18 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
, corruption, or unavailability of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval … materially affect our business.
We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
to adverse impacts.
Furthermore, the loss, corruption, or unavailability of clinical trial data from completed or future clinical trials could result … , embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability
8-K
EX-10.1
ZYME
Zymeworks Inc.
26 Dec 23
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
8:09am
Act of 1977, the Corruption of Foreign Public Officials Act (Canada) or the U.K. Bribery Act 2010, each as may be amended, or similar law of any other … of 1977, the Corruption of Foreign Public Officials Act (Canada) or the U.K. Bribery Act 2010, each as may be amended, or similar law of any other
8-K
EX-10.1
prrl2ye1xm ucbuaasck
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
r8fcyty8
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
1ye2sniuvdo8x8 1os77
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-1.1
pyc31a w2j
9 Nov 22
Entry into a Material Definitive Agreement
4:50pm
424B5
yzauqx4 c02t6
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
5qqwj08jejy
8 Nov 22
Quarterly report
4:09pm
8-K
EX-1.1
v2tpt1lvz9ah4qa qjwy
21 Oct 22
Entry into a Material Definitive Agreement
4:19pm
424B5
e5dy227
21 Oct 22
Prospectus supplement for primary offering
4:16pm
424B5
gwdedgeetwvmq0n0or
13 Oct 22
Prospectus supplement for primary offering
4:56pm
8-K12B
EX-14.1
vb3g3v
13 Oct 22
Notification of registration of securities
7:24am
- Prev
- 1
- Next